Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Mar 14, 2018)
  • 8-K (Jan 19, 2018)
  • 8-K (Jan 17, 2018)
  • 8-K (Dec 28, 2017)
  • 8-K (Dec 11, 2017)
  • 8-K (Dec 6, 2017)

 
Other

AstroNova, Inc. 8-K 2005

Documents found in this filing:

  1. 8-K
  2. 8-K
Form 8-K Braintree
                UNITED STATES SECURITIES AND EXCHANGE COMMISSION


                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                                 DATE OF REPORT
                        (DATE OF EARLIEST EVENT REPORTED)

                                  June 17, 2005



                                 ASTRO-MED, INC
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


                         COMMISSION FILE NUMBER 0-13200



RHODE ISLAND                                                          05-0318215
(STATE OR OTHER JURISDICTION OF                     (IRS EMPLOYER IDENTIFICATION
INCORPORATION OR ORGANIZATION)                                           NUMBER)


                600 EAST GREENWICH AVENUE, WEST WARWICK, RI 02893
          (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)


                                 (401-828-4000)
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)












ITEM 1.01.  ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.

     On June 17, 2005, Astro-Med, Inc. (the "Company") entered into an agreement
with  Hanover  R.S.  Limited  Partnership,  a  Texas  limited  partnership  (the
"Purchaser") with a principal  business address of 5847 San Felipe,  Suite 3600,
Houston,  Texas, for the sale of  approximately  24.692 acres of land located in
Braintree,  Massachusetts owned by the Company (the "Property") for the purchase
price of $6,100,000 to be paid in cash at the closing.  The sale of the Property
is subject to a 90 day feasibility  period ending on September 17, 2005,  during
which time the  Purchaser may inspect the Property and terminate the sale due to
any adverse  conditions  discovered on the Property.  Following the  feasibility
period,  the Purchaser shall have 16 months to obtain final zoning and site plan
approval from all state and local governmental  entities for use of the Property
as a multi-family residential rental property,  subject to two 30 day extensions
exercisable  at the  option of the  Purchaser  upon  payment  to the  Company of
$25,000 per extension.

     Upon  execution of the  agreement,  $250,000 of earnest money was placed in
escrow pending completion of the sale and an additional $250,000 is to be placed
in escrow at the expiration of the feasibility period. Following the feasibility
period,  all such earnest  money is forfeited by the Purchaser in the event that
the sale is not  completed due to a breach by the  Purchaser.  In the event of a
termination of the agreement by the Purchaser during the feasibility period, all
earnest  money is to be  returned  to the  Purchaser,  less  $5,000.

ITEM 9.01. FINANCIAL  STATEMENTS  AND  EXHIBITS

(c)  Exhibits

Exhibit No.  Exhibit

None.

SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrants  have duly caused  this  report to be signed on their  behalf by the
undersigned thereunto duly authorized.

DATE: June 20, 2005                 ASTRO-MED, INC.



                                    By: /s/Joseph P. O'Connell
                                         ------------------------------
                                           Joseph P. O'Connell
                                           Vice President, Treasurer and
                                           Chief Financial Officer


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki